Trusted by the world’s leading institutions
A multi-institutional clinical study led by Roswell Park Cancer Institute has demonstrated the safety and effectiveness of a chemoimmunotherapy treatment for patients with non-Hodgkin's lymphoma. The overall response rate was 95% for patients who received treatment with a combination of Rituxan, a monoclonal antibody, and the systemic standard dose chemotherapy regimen used for this disease.
The long-term, worldwide trend of increasing breast cancer mortality rates apparently has been reversed in several countries, with significant declines reported in the United States, the United Kingdom and Canada in the 1990s. These are the findings of a study conducted at Roswell Park Cancer Institute and published in the May/June 1999 issue of CA -- A Cancer Journal for Physicians.
Preliminary results of a pilot and a Phase II study using Rituximab to treat non-Hodgkin's lymphoma were presented at the American Society of Clinical Oncology meeting in Atlanta. These studies show Rituximab to be effective when combined with Fludarabine (a chemotherapy) and when used alone dosed in an extended eight-infusion regimen. Both trials were conducted at Roswell Park Cancer Institute and other cancer centers.
Novel genetic factors contribute to the incidence of colorectal cancer among a percentage of African-Americans, according to the results of a pioneering study conducted by a research team headed by Thomas K. Weber, MD, FACS, of the Division of Surgery, Roswell Park Cancer Institute. Their report will appear in the June 23, 1999 edition of the Journal of the American Medical Association.
Roswell Park Cancer Institute scientists have found that the level of gelsolin, a protein responsible for maintaining actin filaments that are needed for healthy cells, may be of diagnostic and therapeutic value for breast cancer.
The first study to evaluate the impact of cardiac disease and second malignant neoplasms on late mortality and to identify risk factors for late mortality among 15-year survivors of cancer diagnosed during childhood or adolescence has concluded that survivors who relapsed during the 15-year period have excess mortality.
Research on colorectal cancer tumors and premalignant polyps, published in the December 21 issue of the Proceedings of the National Academy of Sciences, show that cancer arises from a decade or more of cellular changes.
The lessons from California's aggressive tobacco control intervention program, which has resulted in a continuing decline in adult smoking, may help to decrease adult smoking throughout the U.S., according to a study in the March American Journal of Public Health.
Childhood survivors of Hodgkin's disease have a substantial risk for second malignant neoplasms, according to research published in today's Journal of Clinical Oncology.
There is a strong push to find methods that may improve survival of Lung cancer by diagnosing the disease at an earlier, presumably more curable, stage. However, whether early detection results in a higher number of cured patients remains unclear. (NEJM, 11-30-00)
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right